HK1108845A1 - Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device - Google Patents

Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Info

Publication number
HK1108845A1
HK1108845A1 HK07113937.2A HK07113937A HK1108845A1 HK 1108845 A1 HK1108845 A1 HK 1108845A1 HK 07113937 A HK07113937 A HK 07113937A HK 1108845 A1 HK1108845 A1 HK 1108845A1
Authority
HK
Hong Kong
Prior art keywords
agent
stimulates
delivery device
therapeutic use
prostacyclin production
Prior art date
Application number
HK07113937.2A
Other languages
English (en)
Inventor
John Francis Martin
Seppo Ylae-Herttuala
Stephen George Edward Barker
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622852.3A external-priority patent/GB9622852D0/en
Priority claimed from GBGB9709494.0A external-priority patent/GB9709494D0/en
Priority claimed from GBGB9717791.9A external-priority patent/GB9717791D0/en
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of HK1108845A1 publication Critical patent/HK1108845A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • External Artificial Organs (AREA)
HK07113937.2A 1996-11-01 2007-12-20 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device HK1108845A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9622852.3A GB9622852D0 (en) 1996-11-01 1996-11-01 Treatment of intimal hyperplasma
GBGB9709494.0A GB9709494D0 (en) 1997-05-09 1997-05-09 Delivery device and method
GBGB9717791.9A GB9717791D0 (en) 1997-08-21 1997-08-21 Treatment of intimal hyperplasia

Publications (1)

Publication Number Publication Date
HK1108845A1 true HK1108845A1 (en) 2008-05-23

Family

ID=27268562

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07113937.2A HK1108845A1 (en) 1996-11-01 2007-12-20 Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device

Country Status (15)

Country Link
US (1) US7320679B2 (fr)
EP (2) EP0941116B1 (fr)
JP (3) JP2001503755A (fr)
KR (1) KR100695590B1 (fr)
AT (1) ATE287271T1 (fr)
AU (1) AU729420B2 (fr)
CA (1) CA2270286C (fr)
DE (1) DE69732304T2 (fr)
ES (1) ES2235227T3 (fr)
HK (1) HK1108845A1 (fr)
HU (1) HU223957B1 (fr)
NO (1) NO326303B1 (fr)
PL (1) PL189744B1 (fr)
PT (1) PT941116E (fr)
WO (1) WO1998020027A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
EP1019082B2 (fr) 1997-10-02 2008-06-04 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Utiliastion d'un facteur des colonies (csf) pour augmenter la croissance collaterale des arteres collaterales et/ou d'autres arteres a partir de connexions arteriolaires preexistantes
GB9809082D0 (en) 1998-04-28 1998-06-24 Eurogene Limited Delivery device
IL141687A0 (en) * 1998-09-09 2002-03-10 Scios Inc Treatment of microvascular angiopathies
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
CA2370404A1 (fr) * 1999-04-26 2000-11-02 Serge Adnot Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
FR2792531B1 (fr) * 1999-04-26 2003-01-31 Aventis Pharma Sa Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
EP1220679B1 (fr) * 1999-09-23 2007-06-13 An-Go-Gen Inc. Therapie genique cellulaire pour le systeme pulmonaire
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド ｅＮＯＳ活性の調節とその治療的使用
SE0000285D0 (sv) * 1999-12-07 2000-01-31 Mika Lahtinen Medical implant
AU3988401A (en) 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
GB0012997D0 (en) * 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
EP1392837A2 (fr) * 2001-05-29 2004-03-03 Ark Therapeutics Limited Transfert genique de vecteur viral
CA2453210A1 (fr) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Dispositifs anti-arythmie et leurs utilisations
SE0102578L (sv) * 2001-07-20 2003-01-21 Oeyvind Reitan Förändring av en stents egenskaper för att förhindra restenos
WO2004113384A1 (fr) * 2003-06-18 2004-12-29 Georg-August-Universität Göttingen Utilisation d'un gene ou d'un produit genetique du recepteur de vegf
GB0515140D0 (en) * 2005-07-22 2005-08-31 Ark Therapeutics Ltd Therapeutic device
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
ES2396440T3 (es) * 2006-01-18 2013-02-21 The General Hospital Corporation Métodos de aumentar la función linfática
US8721711B2 (en) 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
US8808255B2 (en) 2007-12-14 2014-08-19 Oregon Health & Science University Drug delivery cuff
DE102008002396A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Implantierbares Wirkstoffreservoir und Vorrichtung mit einem implantierbaren Wirkstoffreservoir
HUE036640T2 (hu) * 2012-02-14 2018-07-30 Univ California Parakrin gének szisztémás bejuttatása és szabályozott expressziója szív és érrendszeri betegségekre és egyéb állapotokra
WO2013135266A1 (fr) 2012-03-12 2013-09-19 Gemvax As Traitement du cancer du poumon non à petites cellules par immunothérapie active
WO2014022373A1 (fr) 2012-08-01 2014-02-06 United Therapeutics Corporation Traitement de l'hypertension artérielle pulmonaire avec des cellules souches mésenchymateuses
US10080730B2 (en) * 2013-01-09 2018-09-25 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
WO2018080990A1 (fr) 2016-10-24 2018-05-03 United Therapeutics Corporation Amélioration de propriétés immunomodulatrices des csm par le tréprostinil
EP3950708A4 (fr) * 2019-04-05 2022-06-08 Korea Institute of Ceramic Engineering and Technology Procédé d'expression et de purification de protéine à l'aide d'une étiquette csq
IT201900012537A1 (it) * 2019-07-22 2021-01-22 Milano Politecnico Dispositivo di condizionamento per condizionare un tratto esposto di un vaso sanguigno e metodo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797485A (en) * 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
JPS56122317A (en) * 1980-02-29 1981-09-25 Koken:Kk Drug transporting material and its preparation
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5201728A (en) * 1991-05-03 1993-04-13 Giampapa Vincent C Subcutaneous implantable multiple-agent delivery system
US5399352A (en) * 1993-04-14 1995-03-21 Emory University Device for local drug delivery and methods for using the same
CA2164632A1 (fr) * 1993-06-11 1994-12-22 John P. Cooke Traitement de maladies vasculaires degeneratives par modulation de la production ou de l'activite d'oxyde nitrique endogene
US5653744A (en) * 1995-04-27 1997-08-05 Khouri Biomedical Research, Inc. Device and method for vascular anastomosis
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor

Also Published As

Publication number Publication date
KR100695590B1 (ko) 2007-03-14
JP2008155036A (ja) 2008-07-10
HU223957B1 (hu) 2005-03-29
JP4783797B2 (ja) 2011-09-28
PL333272A1 (en) 1999-11-22
DE69732304D1 (de) 2005-02-24
ES2235227T3 (es) 2005-07-01
CA2270286A1 (fr) 1998-05-14
HUP9902867A3 (en) 2001-12-28
EP0941116B1 (fr) 2005-01-19
DE69732304T2 (de) 2005-06-02
WO1998020027A2 (fr) 1998-05-14
KR20000052999A (ko) 2000-08-25
US20030225020A1 (en) 2003-12-04
AU729420B2 (en) 2001-02-01
US7320679B2 (en) 2008-01-22
WO1998020027A3 (fr) 1998-10-08
ATE287271T1 (de) 2005-02-15
CA2270286C (fr) 2009-03-03
PL189744B1 (pl) 2005-09-30
PT941116E (pt) 2005-05-31
JP2001503755A (ja) 2001-03-21
NO992106D0 (no) 1999-04-30
NO992106L (no) 1999-06-30
HUP9902867A2 (hu) 1999-12-28
EP0941116A2 (fr) 1999-09-15
EP1488761A1 (fr) 2004-12-22
NO326303B1 (no) 2008-11-03
AU4790697A (en) 1998-05-29
JP2012031196A (ja) 2012-02-16

Similar Documents

Publication Publication Date Title
HK1108845A1 (en) Therapeutic use of an agent that stimulates no or prostacyclin production and delivery device
PL340096A1 (en) Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein
WO1996004955A3 (fr) Systeme et methode d'apport de medicaments par matrice polymere
NZ266475A (en) Use of recombinant adenovirus of animal origin in making pharmaceutical composition
UA32429C2 (uk) Засіб для лікування нетримання сечі
TW349024B (en) Freeze-dried liposome delivery system for application of skin treatment agents
PL309398A1 (en) Interferon containing therapeutic composition
TW250435B (fr)
AU4634089A (en) Needle and therapeutic device for stimulating specific points of the body
GB9321061D0 (en) Analgestic agent and its use
MY164077A (en) Compositions and uses of et743 for treating cancer
EP0324802A4 (en) Method for the treatment of body tissues and the administration of drugs thereto
GR3022030T3 (en) Composition for treating mastitis and metritis
WO2004064786A3 (fr) Article de parage et de detoxification de blessures
UA42685C2 (uk) Спосіб судинорозширювальної терапії
WO2000000184A8 (fr) Traitement de la sclerose en plaques
HK1032360A1 (en) Combination therapy for the treatment of tumors.
UA37509A (uk) Спосіб лікування фето-плацентарної недостатності
ES8500951A1 (es) Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
粟坪华 et al. Observation on 38 cases of drug-induced myospasm treated with massage over the acupoints
马天伟 43 CASES OF POSTOPERATIVE GASTROINTESTINAL DYSFUNCTION TREATED WITH ACUPUNCTURE PLUS AURICULAR-PLASTER THERAPY
王润 Treatment of 40 cases of hydroceles with massage at Qichong (ST 30)
ZA93199B (en) An apparatus for use in therapeutic and/or medical treatment.
GB8910474D0 (en) Device for the use in treatment of the human body

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141103